Search clinical trials for: AZD7325

Total 67 results

AstraZeneca

Recruiting

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

Ovarian Cancer | Lung Adenocarcinoma

Spain, China, United States, Australia, Taiwan, Canada, Israel, Japan, United Kingdom
AstraZeneca

Suspended

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

Metabolism | Absorption | Distribution | Excretion

United Kingdom
AstraZeneca

Completed

AZD7325 Multiple Ascending Dose Study (MAD)

Healthy Volunteer

United States
AstraZeneca

Completed

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Anxiety Disorders

United States
AstraZeneca

Completed

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects (JSAD)

Healthy Volunteer

United States
University College, London

Completed

Effects of GABA Modulator AZD7325 on Cortical Excitability

Healthy

United Kingdom
Children's Hospital Medical Center, Cincinnati

Completed

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

Fragile X Syndrome

United States
AstraZeneca

Terminated

AZD7325 Japan Multiple Ascending Dose (MAD) Study (JMAD)

Healthy
University of California, Los Angeles

Completed

Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial (FAST-AS)

Autism Spectrum Disorder

United States
University College, London

Completed

Effects of GABA Modulator AZD7325 on Cutaneous Sensation

Healthy

United Kingdom
AstraZeneca

Completed

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305 (2007-005765-38)

Healthy

United Kingdom
AstraZeneca

Completed

Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Atrial Fibrillation

Sweden, Czech Republic, Hungary, Poland, Netherlands, Norway, Denmark, Slovakia
AstraZeneca

Completed

Explorative Study of AZD1305 in Atrial Fibrillation Patients

Atrial Fibrillation

Russian Federation, Poland, Denmark, Norway, Slovakia, Sweden
AstraZeneca

Completed

To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328

Healthy

Sweden
AstraZeneca

Completed

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

Healthy

Sweden
AstraZeneca

Terminated

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

Schizophrenia

United States
AstraZeneca

Completed

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Healthy

United Kingdom
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, Germany, China, Japan
AstraZeneca

Completed

Cardiac Electrophysiological Study

Atrial Flutter

Finland, Norway, Denmark, Sweden
AstraZeneca

Completed

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

Healthy

United Kingdom
AstraZeneca

Completed

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

A Study Conducted Over 3 Periods to Look at the Drug in the Body

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca

Terminated

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects (JMAD)

Healthy

United States
Arrow Therapeutics

Completed

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

Healthy

United Kingdom
AstraZeneca

Completed

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Left Ventricle Function

Sweden
AstraZeneca

Completed

Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

Anxious Major Depressive Disorder

United States
AstraZeneca

Completed

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Healthy Subjects

Japan
Arrow Therapeutics

Completed

Pharmacokinetics of AZD7295 Capsules

Healthy

United Kingdom
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
King's College London
AstraZeneca; Helse Stavanger HF; Michael J. Fox Foundation for Parkinson's Research and other collaborators

Withdrawn

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug (PD-MIND)

Parkinson Disease | Mild Cognitive Impairment
AstraZeneca

Completed

Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese

Healthy Volunteers

United Kingdom
AstraZeneca

Suspended

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Pharmacokinetics

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329 (AZ8329)

Healthy | Overweight | Male

United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects

Alzheimer's Disease

Sweden
AstraZeneca

Completed

A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses

Healthy Men

Sweden
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 (PET)

Anxiety

Sweden
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan

Unknown

Lesogaberan in Chinese Patients With Refractory Reflux Symptoms

Gastroesophageal Reflux Disease

Taiwan
AstraZeneca

Completed

To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients

Healthy Subjects | COPD

United Kingdom
AstraZeneca

Completed

Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge

LPS Challenge, Neutrophils

United Kingdom
AstraZeneca

Completed

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

Anxiety Disorders

United States
AstraZeneca

Completed

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

Recreational CNS Depressant Use

Canada
AstraZeneca

Completed

An Interaction Study With Digoxin and AZD1305

Atrial Fibrillation

Sweden
AstraZeneca

Completed

Study to Compare Different Formulations of AZD3355

Gastroesophageal Reflux Disease

Sweden
AstraZeneca

Completed

A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Completed

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

Healthy Volunteer

Netherlands
AstraZeneca

Completed

TLESR-impedance Study in Patients

Reflux Episodes
AstraZeneca

Completed

Renal Impairment Study

Reflux | Renal Excretion

Sweden

3

Subscribe